Anakinra

Active ingredient description

Anakinra neutralises the biologic activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by competitively inhibiting their binding to interleukin-1 type I receptor (IL-1RI). Interleukin-1 (IL-1) is a pivotal pro-inflammatory cytokine mediating many cellular responses including those important in synovial inflammation.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L04AC03
Anakinra
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC03

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
KINERET Solution for injection
Summary of Product Characteristics (SPC)

Chemical formula: C₂₀H₂₃N₅O₇S₂
Molecular mass: 509.6 g/mol

3D molecular structure

3D representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 143090-92-0
DrugBank Drug: DB00026
KEGG Drug: D02934
RxNorm Ingredient: 72435
SNOMED-CT Concept: 385549000
Anakinra (substance)
UNII Identifier: 9013DUQ28K
ANAKINRA

Medicines

Anakinra is an active ingredient of these brands:

United States (US)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Australia (AU)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Austria (AT)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Canada (CA)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Cyprus (CY)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Estonia (EE)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Finland (FI)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

France (FR)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Ireland (IE)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Lithuania (LT)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Netherlands (NL)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Poland (PL)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Romania (RO)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

Spain (ES)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

United Kingdom (UK)

  • KINERET as Recombinant human interleukin-1 receptor antagonist

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.

 
Next: Usage >